Mark Rutstein

1.7k citations

26 papers · 1.3k indexed · h-index 9

Impact in

Behavioral Neuroscience top 2%
- Stress Responses and Cortisol
Hematology top 2%
- Platelet Disorders and Treatments
- Blood groups and transfusion

Papers in ⓘ

Oncology 14
- Colorectal Cancer Treatments and Studies 6
- Cancer Treatment and Pharmacology 5
- Cancer Immunotherapy and Biomarkers 4
Hematology 7
- Platelet Disorders and Treatments 5

Co-authors: Susan L. Andersen (2 shared papers)Martin H. Teicher (2 shared papers)Lin Li (1 shared paper)Jon P. Fryzek (1 shared paper)James A. Kaye (1 shared paper)Gena Kucera (1 shared paper)Fionna Mowat (1 shared paper)W. Marieke Schoonen (1 shared paper)
Journals: Journal of Clinical Oncology (10 papers)Blood (3 papers)Annals of Oncology (2 papers)British Journal of Haematology (1 paper)Journal of the American Society of Nephrology (1 paper)
Partner nations: United States Germany Italy

In The Last Decade

Mark Rutstein

26 papers receiving 1.2k citations

Peers

Countries citing papers authored by Mark Rutstein

Since Specialization

Citations

This map shows the geographic impact of Mark Rutstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Rutstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Rutstein more than expected).

Fields of papers citing papers by Mark Rutstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Rutstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Rutstein. The network helps show where Mark Rutstein may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Rutstein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Rutstein Line = papers co-authored together Mark Rutstein links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Dopamine receptor pruning in prefrontal cortex during the periadolescent period in rats Synapse ·Susan L. Andersen, Andrew T. Thompson, Mark Rutstein, John C. Hostetter, Martin H. Teicher	2000	351
2	Sex differences in dopamine receptor overproduction and elimination Neuroreport ·Susan L. Andersen, Mark Rutstein, J Benzo, John C. Hostetter, Martin H. Teicher	1997	272
3	Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database British Journal of Haematology ·W. Marieke Schoonen, Gena Kucera, Jenna E. Coalson, Lin Li, Mark Rutstein, Fionna Mowat, Jon P. Fryzek, James A. Kaye	2009	215
4	Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim Blood ·David J. Kuter, Ghulam J. Mufti, Barbara J. Bain, Robert P. Hasserjian, Wende Davis, Mark Rutstein	2009	134
5	Pharmacoepidemiology of Anemia in Kidney Transplant Recipients Journal of the American Society of Nephrology ·Wolfgang C. Winkelmayer, Reshma Kewalramani, Mark Rutstein, Steven Gabardi, Tania Vonvisger, Anil Chandraker	2004	111
6	ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer Future Oncology ·Guru Sonpavde, Andrea Necchi, Shilpa Gupta, Gary D. Steinberg, Juergen E. Gschwend, Michiel Simon Van Der Heijden, Nathalie Garzon, Mohammed Ibrahim, Bradley Raybold, Danny Liaw, Mark Rutstein, Matt D. Galsky	2019	69
7	Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences Current Medical Research and Opinion ·Susan D. Mathias, Sue Gao, Mark Rutstein, Claire Snyder, Albert W. Wu, David Cella	2008	22
8	Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial. Journal of Clinical Oncology ·Michael Teufel, Susanne Schwenke, Henrik Seidel, Georg Beckmann, Joachim Reischl, Richardus Vonk, Heinz‐Josef Lenz, Josep Tabernero, Salvatore Siena, Axel Grothey, Eric Van Cutsem, Michael Jeffers, Scott M. Wilhelm, Thierry André, Dirk Laurent, Svetlana Kobina, Mark Rutstein, Pratyaksha Wirapati, Justin Guinney, Sabine Tejpar	2015	20
9	9209 Safety of romiplostim for treatment of severe chemotherapy induced thrombocytopenia (CIT) in patients with lymphoma receiving multi-cycle chemotherapy: results from an open-label dose- and schedule-finding study European Journal of Cancer Supplements ·Michelle A. Fanale, Pat Stiff, Krista Noonan, John McCoy, Mark Rutstein, Craig H. Moskowitz	2009	8
10	A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205 with or without intravesical Bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC): CheckMate 9UT. Journal of Clinical Oncology ·Noah M. Hahn, Sam S. Chang, Maxwell V. Meng, Neal D. Shore, Badrinath R. Konety, Gary D. Steinberg, Juergen E. Gschwend, Hiroyuki Nishiyama, Juan Palou Redorta, John A. Taylor, Ayanbola Elegbe, Alexandre Lambert, Li Zhu, Yuko Ishii, Toshiki Maeda, Bradley Raybold, Gary D. Grossfeld, Bruce S. Fischer, Mark Rutstein, Alfred Witjes	2019	8
11	Long-Term Safety Profile of Romiplostim in Patients with Chronic Immune Thrombocytopenia (ITP). Blood ·Howard A. Liebman, David Henry, François Lefrère, Jean‐François Viallard, Alan Lichtin, James N. George, Miguel Á. Sanz, Kathy Zhang, Mark Rutstein	2008	8
12	A phase II, open-label, multicenter study of IMC-1121B (ramucirumab; RAM) monotherapy in the treatment of persistent or recurrent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal (PPC) carcinoma (CP12-0711/NCT00721162). Journal of Clinical Oncology ·Richard T. Penson, Kathleen N. Moore, Gini F. Fleming, Patricia S. Braly, Veronica Schimp, Hoa Nguyen, Ursula A. Matulonis, Susana Banerjee, Paul Haluska, Martin Gore, Diane C. Bodurka, А. А. Морозов, Yihuan Xu, Mark Rutstein, Jonathan D. Schwartz, William P. McGuire	2012	7
13	Randomized phase II study of capecitabine with or without ramucirumab (IMC-1121B) or IMC-18F1 in patients with unresectable, locally advanced or metastatic breast cancer (mBC) previously treated with anthracycline and taxane therapy (CP20-0903/NCT01234402). Journal of Clinical Oncology ·Linda T. Vahdat, K Miller, J. A. Sparano, Hagop Youssoufian, J. D. Schwartz, Santosh K. Nanda, W. Wang, Leslie W. Abad, Aruna Dontabhaktuni, Mark Rutstein	2011	7
14	A phase 3 randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± BMS-986205 in cisplatin-eligible muscle invasive bladder cancer (MIBC). Journal of Clinical Oncology ·Guru Sonpavde, Andrea Necchi, Shilpa Gupta, Gary D. Steinberg, Juergen E. Gschwend, Michiel Simon Van Der Heijden, Nathalie Garzon, Ayanbola Elegbe, Bradley Raybold, Danny Liaw, Mark Rutstein, Matt D. Galsky	2019	7
15	Analysis of plasma protein biomarkers from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology ·Michael Teufel, J. Kalmus, Mark Rutstein, Karl Koechert, Henrik Seidel, Joachim Reischl, Adam Skubala, Richardus Vonk, Scott M. Wilhelm, Svetlana Kobina, Shukui Qin, Rui‐Hua Xu, Tae Won Kim, Jin Li	2016	6
16	A randomized, double-blind, phase (Ph) III study of the irinotecan-based chemotherapy FOLFIRI plus ramucirumab (RAM) or placebo (PL) in patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (RAISE) (NCT01183780). Journal of Clinical Oncology ·Axel Grothey, Josep Tabernero, Philippe Rougier, Shaila Ballal, Heidi M. Crane, Mark Rutstein	2012	5
17	Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in subjects with extensive-disease small cell lung cancer (ED-SCLC) Annals of Oncology ·Martin Reck, Leora Horn, Silvia Novello, Fabrice Barlési, István Albert, Erzsébet Juhász, J.W.N.C. Huang Foen Chung, Arno Fritsch, Uta Drews, Mark Rutstein, (unknown), Ramaswamy Govindan	2016	4
18	2013 Analysis of biomarkers in circulating tumor DNA from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC): Correlation with clinical outcome European Journal of Cancer ·Michael Teufel, J. Kalmus, Mark Rutstein, Karl Köchert, Henrik Seidel, Joachim Reischl, A. Skubula, Richardus Vonk, Sue Wilhelm, Svetlana Kobina, Sida Qin, Rui‐Hua Xu, T.W. Kim, J. Li	2015	4
19	A phase (Ph) Ib study of irinotecan (IRI), levofolinate (LV), and 5-fluorouracil (5-FU) (FOLFIRI) plus ramucirumab (RAM; IMC-1121B) drug product in Japanese (JP) patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (CP12-1029/NCT01286818). Journal of Clinical Oncology ·Takayuki Yoshino, Kentaro Yamazaki, Motoki Yoshida, Mark Rutstein, Naoto Yoshizuka, Atsushi Ohtsu	2013	4
20	A phase 2, randomized study of nivolumab or nivolumab plus BMS-986205 with or without intravesical bacillus Calmette-Guerin in patients with bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer: CheckMate 9UT European Urology Supplements ·J.A. Witjes, J. Gschwend, J. Palou, Mei Meng, Sam S. Chang, Neal D. Shore, Badrinath R. Konety, Gregory R. Steinberg, Hiroyuki Nishiyama, Jack A. Taylor, Ayanbola Elegbe, Alexandre Lambert, Liangru Zhu, Y Ishii, Toshiki Maeda, Bradley Raybold, Gary D. Grossfeld, Barbara Fischer, Mark Rutstein, Noah M. Hahn	2019	4

About Mark Rutstein

Mark Rutstein is a scholar working on Oncology, Hematology, Molecular Biology, Genetics and Cancer Research, having authored 26 papers that have together received 1.3k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (5 papers), Bladder and Urothelial Cancer Treatments (5 papers), Platelet Disorders and Treatments (5 papers), Chronic Lymphocytic Leukemia Research (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), Cancer Genomics and Diagnostics (3 papers) and Angiogenesis and VEGF in Cancer (3 papers). The work is most often cited by research in Behavioral Neuroscience (188 citations), Hematology (442 citations), Biological Psychiatry (64 citations), Transplantation (66 citations) and Cellular and Molecular Neuroscience (402 citations). Mark Rutstein has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include Susan L. Andersen, Martin H. Teicher, Lin Li, Jon P. Fryzek, James A. Kaye, Gena Kucera, Fionna Mowat, W. Marieke Schoonen, Jenna E. Coalson and Barbara J. Bain. Their work appears in journals such as Journal of Clinical Oncology, Blood, Annals of Oncology, British Journal of Haematology and Journal of the American Society of Nephrology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact